Skip to main content

Table 2 Baseline patient demographics: safety population BENEFIT-Korea study

From: Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Variable

Male (n = 1871)

Female (n = 1269)

Total (n = 3140)

Age (yr)

  < 50

359 (11.4)

124 (4.0)

483 (15.4)

 50–69

976 (31.1)

508 (16.2)

1484 (47.3)

  ≥ 70

536 (17.1)

637 (20.3)

1173 (37.4)

Height (cm)a

168.7 ± 6.7

154.2 ± 6.1

162.7 ± 9.6

Body weight (kg)b

73.4 ± 12.5

60.8 ± 10.2

68.1 ± 13.2

Waist circumference (cm)c

90.0 ± 9.0

84.4 ± 9.6

87.7 ± 9.6

BMI (kg/m2)d

25.7 ± 3.5

25.5 ± 4.0

25.6 ± 3.8

Cardiocerebrovascular risk factors present

1825 (97.5)

1192 (93.9)

3017 (96.1)

 Male ≥45 yr, female ≥55 yr

1643 (90.0)

1064 (89.3)

2707 (89.7)

 Current smoker

451 (24.7)

21 (1.8)

472 (15.6)

 BMI ≥25 kg/m2, or waist circumference > 90 cm (male) or > 80 cm (female)

673 (36.9)

455 (38.2)

1128 (37.4)

 Dyslipidemia

911 (49.9)

613 (51.4)

1524 (50.5)

 Impaired fasting glucose or impaired glucose tolerance

42 (2.3)

15 (1.3)

57 (1.9)

 Family history of early cardiocerebrovascular disease (male, < 55 yr, female < 65 yr)

84 (4.6)

69 (5.8)

153 (5.1)

 Diabetes mellitus

549 (30.1)

323 (27.1)

872 (28.9)

Medical history present

1667 (89.1)

1131 (89.1)

2798 (89.1)

 Diseases of circulatory system

1234 (74.0)

773 (68.4)

2007 (71.7)

 Endocrine, nutritional and metabolic diseases

1045 (62.7)

713 (63.0)

1758 (62.8)

 Diseases of genitourinary system

276 (16.6)

123 (10.9)

399 (14.3)

 Diseases of digestive system

138 (8.3)

140 (12.4)

278 (9.9)

 Diseases of musculoskeletal system and connective tissue

98 (5.9)

111 (9.8)

209 (7.5)

Use of concomitant treatment with anti-hypertensives with nebivolol

1460 (78.0)

984 (77.5)

2444 (77.8)

 Calcium antagonists

816 (55.9)

512 (52.0)

1328 (54.3)

 Angiotensin II receptor antagonists

724 (49.6)

583 (59.3)

1307 (53.5)

 Diuretics

299 (20.5)

279 (28.4)

578 (23.7)

 ACE inhibitors

183 (12.5)

42 (4.3)

225 (9.2)

 Alpha-blockers

24 (1.6)

9 (0.9)

33 (1.4)

 Not available

10 (0.7)

2 (0.2)

12 (0.5)

  1. Values are presented as number (%) or mean ± standard deviation
  2. P-value (t-test) for the difference between male and female was significant (P < 0.001) for height, weight, and waist circumference
  3. BMI body mass index, ACE angiotensin-converting enzyme
  4. aHeight measurement: male (1217), female (867). b Body weight measurement: male (1212), female (868). c Waist circumference: male (292), female (208). dBMI: male (1174), female (846)